Weight loss in women taking flibanserin for hypoactive sexual desire disorder (HSDD): Insights into potential mechanisms

Articles

Weight loss in women taking flibanserin for hypoactive sexual desire disorder (HSDD): Insights into potential mechanismsIntroduction: Flibanserin, a multifunctional serotonin receptor agonist and antagonist, is currently approved in the United States and Canada for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. A post hoc analysis of HSDD clinical trial…

Effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with hypoactive sexual desire disorder: a post hoc analysis

Articles

Effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with hypoactive sexual desire disorder: a post hoc analysisBackground: Flibanserin, a 5-HT 1A  agonist and 5-HT 2A  antagonist, is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This post hoc analysis evaluated the effect of flibanserin…